Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Qiagen
MedTech
EQT buys molecular diagnostics specialist Qiagen in a €10.8B deal
EQT is buying up Netherlands-based Qiagen in a deal worth €10.8 billion ($12.1 billion) in enterprise value that includes $1.1 billion in net debt.
Patrick McGuire
Oct 23, 2026 9:58am
Qiagen appoints new chief executive after 9-month search
Aug 24, 2026 11:17am
Qiagen links with Nvidia to propel AI use in drug discovery
May 20, 2026 10:53am
Qiagen launches latest diagnostic for bloodstream infections
Apr 16, 2026 7:55am
Qiagen 'open for discussion' on shareholder value
Feb 6, 2026 9:15am
Qiagen CEO to step down as company snaps up Parse Biosciences
Nov 4, 2025 2:22pm